Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Opdivo for Hepatocellular Carcinoma

Bristol-Myers Squibb news release; 2017 Sep 22

The FDA has granted accelerated approval to Opdivo (nivolumab) injection for intravenous use for the treatment of patients with hepatocellular carcinoma (HCC).

Indications: Opdivo is a programmed death receptor-1 blocking antibody indicated for the treatment of patients with HCC who have been previously treated with sorafenib.

Dosage and administration: 240 mg every 2 weeks.

Efficacy and safety: Approval is based on results from a phase 1/2 open-label study showing that 14% of patients responded to treatment with Opdivo.

Side effects/risks: The most common adverse reactions are fatigue, rash, musculoskeletal pain, pruritus, diarrhea, nausea, asthenia, cough, dyspnea, constipation, decreased appetite, back pain, arthralgia, upper respiratory tract infection, and pyrexia.

Citation:

Bristol-Myers Squibb’s Opdivo (nivolumab) receives FDA approval for the treatment of hepatocellular carcinoma patients previously treated with sorafenib [news release]. Princeton, NJ: Bristol-Myers Squibb Company. September 22, 2017. https://www.astrazeneca.com/media-centre/press-releases/2017/faslodex-re.... Accessed October 1, 2017.

Opdivo [package insert]. Princeton, NJ: Bristol-Myers Squibb Company. 2017. https://packageinserts.bms.com/pi/pi_opdivo.pdf. Accessed October 1, 2017.

This Week's Must Reads

Cochrane on Bisphosphonates for Breast Cancer, Cochrane; 2017 Oct 30; O'Carrigan, Wong, et al

Fiber Intake and Survival After CRC Diagnosis, JAMA Oncol; ePub 2017 Nov 2; Song, Wu, et al

Selecting Patients with Advanced NSCLC for Chemo, JAMA Oncol; ePub 2017 Nov 1; Shen, Chang, et al

Predicting CV Risk in Childhood Cancer Survivors, J Clin Oncol; ePub 2017 Nov 2; Chow, Chen, et al

CD8+ Tumor-Infiltrating Lymphocytes and Ovarian Ca, JAMA Oncol; ePub 2017 Oct 12; OTTA Consortium

Must Reads in FDA Actions

Varubi Approved for Delayed Nausea and Vomiting, Tesaro news release; 2017 Oct 25

FDA Approves Keytruda for Advanced Gastric Ca, Merck news release; 2017 Sep 22

FDA Approves Opdivo for Hepatocellular Carcinoma, Bristol-Myers Squibb news release; 2017 Sep 22

New Indication for Somatuline Depot, Ipsen package insert; 2017 Sep

Verzenio Approved for Certain Breast Cancers, FDA news release; 2017 Sep 28